This phase 1 and 2 trial demonstrated that majority of the patients with CD19-positive Lymphoid tumors who received the CAR-(anti-CD19, CD28.CD3ζ, IL-15, and inducible caspase 9)-UCB-NK cell therapy achieved a rapid response to treatment, and CAR-NK cells maintained their persistence at low levels for at least 12 months. Here, CD19 is linked to lymphoid neoplasm.